Business Context and Reporting Period
This Form 8-K, dated October 5, 2015, reports on events occurring on October 4, 2015, for AtriCure, Inc. The primary event is the entry into a Material Definitive Agreement to acquire nContact Surgical, Inc. ("nContact"). The filing also references preliminary revenue results for the third quarter ended September 30, 2015, though specific figures are contained in an attached press release (Exhibit 99.1) and are not detailed in the text of this report.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed merger with nContact rather than AtriCure's standalone operating metrics for the period.
- Up-Front Consideration: Approximately 3.4 million shares of AtriCure common stock and approximately $8 million in cash.
- Escrow: An additional 304,878 shares of common stock to be deposited for post-closing claims.
- Earn-Out Potential: Additional consideration is available if nContact revenue exceeds an annual growth rate of greater than 25% over a four-year period starting January 1, 2016.
- Regulatory Milestone Payment: An additional $50 million payable upon completion of enrollment for nContact's CONVERGE IDE trial and FDA PMA approval.
- Dilution Cap: The maximum number of shares issued for the transaction, including earn-outs, is capped at 19.9% of AtriCure's outstanding shares prior to the acquisition.
- Liquidity and Debt: The filing does not provide specific data on AtriCure's current cash flow, debt levels, or liquidity ratios. It notes the merger is not conditioned on AtriCure obtaining financing.
Material Changes and Outlook
The material change is the strategic acquisition of nContact, intended to expand AtriCure's product portfolio. The transaction is subject to conditions including nContact stockholder approval and the absence of a material adverse effect on nContact's business. AtriCure stockholder approval is not required.
Management commentary is limited to the terms of the agreement and a reference to a press release regarding Q3 2015 preliminary revenue. The filing includes extensive forward-looking statements regarding the integration of nContact, market acceptance, and regulatory approvals, noting that actual results may differ materially from projections.
Risks and Contingencies
- Transaction Risk: The merger may not occur if conditions are not met.
- Integration Risk: Potential failure to successfully integrate nContact's business or achieve anticipated revenue.
- Regulatory Risk: Delays or failures in obtaining FDA approvals for nContact's products, which are tied to significant earn-out payments.
- Market Risk: Uncertainty regarding market acceptance of new products and competition.
- Legal Disclaimer: Representations and warranties in the Merger Agreement are for the benefit of the parties and should not be relied upon by investors as factual characterizations of the company's condition.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q3 2015 revenue figures, as they are not in the main text.
- Examine the full Merger Agreement (Exhibit 2.1) for detailed definitions of the earn-out milestones and escrow terms.
- Verify the status of nContact's CONVERGE IDE trial enrollment and PMA application timeline.
- Confirm whether nContact stockholders have approved the merger as a condition precedent.
- Assess the impact of issuing up to 19.9% of outstanding shares on existing shareholder dilution.